Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $55.50.

A number of research firms have recently commented on TVRD. Wall Street Zen lowered shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. BTIG Research reissued a “buy” rating and issued a $15.00 price target on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of institutional investors have recently modified their holdings of TVRD. Geode Capital Management LLC bought a new position in shares of Tvardi Therapeutics in the second quarter valued at approximately $2,617,000. JPMorgan Chase & Co. bought a new position in shares of Tvardi Therapeutics in the second quarter valued at approximately $39,000. New York State Common Retirement Fund bought a new position in Tvardi Therapeutics during the second quarter worth $92,000. Marshall Wace LLP bought a new position in Tvardi Therapeutics during the second quarter worth $583,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Tvardi Therapeutics during the second quarter worth $43,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Down 5.0%

NASDAQ TVRD opened at $3.22 on Tuesday. The stock has a market capitalization of $30.20 million, a PE ratio of -0.58 and a beta of 0.16. The company has a 50 day moving average price of $3.52 and a two-hundred day moving average price of $5.64. Tvardi Therapeutics has a 12-month low of $2.75 and a 12-month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Tuesday, March 31st. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23). As a group, equities analysts anticipate that Tvardi Therapeutics will post -2.01 EPS for the current year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.